AstraZeneca’s (LON:AZN) Hold Rating Reaffirmed at Liberum Capital

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by equities researchers at Liberum Capital in a note issued to investors on Thursday, January 18th. They presently have a GBX 5,000 ($69.08) target price on the biopharmaceutical company’s stock. Liberum Capital’s price objective would indicate a potential upside of 2.88% from the stock’s current price.

A number of other research firms have also recently commented on AZN. JPMorgan Chase & Co. set a GBX 5,500 ($75.99) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Thursday, January 4th. Sanford C. Bernstein set a GBX 5,780 ($79.86) target price on AstraZeneca and gave the stock a “buy” rating in a report on Monday, September 25th. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a report on Tuesday, October 31st. HSBC lifted their target price on AstraZeneca from GBX 4,340 ($59.96) to GBX 4,380 ($60.51) and gave the stock a “reduce” rating in a report on Thursday, November 16th. Finally, UBS Group set a GBX 4,550 ($62.86) target price on AstraZeneca and gave the stock a “neutral” rating in a report on Monday, October 9th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of GBX 5,211.65 ($72.00).

AstraZeneca (LON AZN) opened at GBX 4,860 ($67.15) on Thursday. AstraZeneca has a 52-week low of GBX 4,260 ($58.86) and a 52-week high of GBX 5,520 ($76.26). The company has a market cap of $61,540.00 and a price-to-earnings ratio of 2,858.82.

In other news, insider Philip A. J. Broadley bought 415 shares of the stock in a transaction dated Friday, February 2nd. The shares were bought at an average cost of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).

ILLEGAL ACTIVITY WARNING: “AstraZeneca’s (LON:AZN) Hold Rating Reaffirmed at Liberum Capital” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/13/astrazeneca-azn-earns-hold-rating-from-liberum-capital.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply